RO117145B1 - Emulsie sau soluţie apoasă, mucoadezivă - Google Patents

Emulsie sau soluţie apoasă, mucoadezivă

Info

Publication number
RO117145B1
RO117145B1 RO96-02162A RO9602162A RO117145B1 RO 117145 B1 RO117145 B1 RO 117145B1 RO 9602162 A RO9602162 A RO 9602162A RO 117145 B1 RO117145 B1 RO 117145B1
Authority
RO
Romania
Prior art keywords
aqueous solution
emulsion
mucoadhesive
mucoadhesive emulsion
itraconazole
Prior art date
Application number
RO96-02162A
Other languages
English (en)
Inventor
Peter Putteman
Marc Karel Jozef Francois
Eric Carolus Leonarda Snoeckx
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of RO117145B1 publication Critical patent/RO117145B1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Invenţia se referă la emulsie sau soluţie apoasă, mucoadezivă, utilizată în tratamentul medical. Emulsia conform invenţiei este constituită din 10...70% ciclodextrină sau un derivat al acesteia, 0,1...5% itraconazol, 0,05...5% agent de îngroşare, 0,5...10% emulgator, 0,5...10% agent de stabilizare, 0,5...50% ulei acceptabil farmaceutic, un tampon alcătuit din acid sau bază, pentru a menţine pH-ul între 1 şi 4, procentele fiind exprimate în greutate.
RO96-02162A 1994-05-18 1995-05-10 Emulsie sau soluţie apoasă, mucoadezivă RO117145B1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94201402 1994-05-18
PCT/EP1995/001760 WO1995031178A1 (en) 1994-05-18 1995-05-10 Mucoadhesive emulsions containing cyclodextrin

Publications (1)

Publication Number Publication Date
RO117145B1 true RO117145B1 (ro) 2001-11-30

Family

ID=8216883

Family Applications (1)

Application Number Title Priority Date Filing Date
RO96-02162A RO117145B1 (ro) 1994-05-18 1995-05-10 Emulsie sau soluţie apoasă, mucoadezivă

Country Status (30)

Country Link
US (1) US5814330A (ro)
EP (1) EP0759741B1 (ro)
JP (1) JP3862748B2 (ro)
KR (1) KR100369703B1 (ro)
CN (1) CN1091590C (ro)
AP (1) AP731A (ro)
AT (1) ATE174790T1 (ro)
AU (1) AU680767B2 (ro)
BG (1) BG62754B1 (ro)
BR (1) BR9507873A (ro)
CZ (1) CZ285606B6 (ro)
DE (1) DE69506857T2 (ro)
DK (1) DK0759741T3 (ro)
EE (1) EE03304B1 (ro)
ES (1) ES2127529T3 (ro)
FI (1) FI964589A (ro)
HK (1) HK1010688A1 (ro)
HU (1) HU218082B (ro)
IL (1) IL113742A (ro)
MY (1) MY113846A (ro)
NO (1) NO309507B1 (ro)
NZ (1) NZ285761A (ro)
OA (1) OA10321A (ro)
PL (1) PL179619B1 (ro)
RO (1) RO117145B1 (ro)
RU (1) RU2164418C2 (ro)
SK (1) SK282623B6 (ro)
TW (1) TW438601B (ro)
WO (1) WO1995031178A1 (ro)
ZA (1) ZA954023B (ro)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2188802T3 (es) * 1995-11-28 2003-07-01 Univ Johns Hopkins Med Vectores viricos de replicacion condicional y su uso.
ATE279173T1 (de) * 1996-10-24 2004-10-15 Procter & Gamble Verfahren zur verminderung von körpergeruch
US6416779B1 (en) * 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
WO1999033467A1 (en) 1997-12-31 1999-07-08 Choongwae Pharma Corporation Method and composition of an oral preparation of itraconazole
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
NZ330726A (en) * 1998-06-18 2000-10-27 Dec Res Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate
GB9920167D0 (en) * 1999-08-25 1999-10-27 Avery Dennison Corp Pressure sensitive adhesive compositions
AU1911400A (en) * 1999-11-09 2001-06-06 Procter & Gamble Company, The Cyclodextrin compositions for odor, insect and dust mite contol
US6835717B2 (en) * 2000-03-08 2004-12-28 The Johns Hopkins University School Of Medicine β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases
KR100388605B1 (ko) * 2000-06-13 2003-06-25 코오롱제약주식회사 용해도 및 용해속도가 향상된 이트라코나졸의 액상 조성물 및 이를 이용한 이트라코나졸 제제와 그 제조방법
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US7544348B2 (en) 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
NZ549469A (en) 2001-02-15 2009-02-28 Access Pharma Inc Liquid formulations for the prevention and treatment of mucosal diseases and disorders
AU2002350115A1 (en) * 2001-11-01 2003-05-12 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
CN100384865C (zh) * 2001-11-02 2008-04-30 嵌入治疗公司 用于rna干扰的治疗用途的方法及组合物
US20030144362A1 (en) * 2002-01-28 2003-07-31 Utterberg David S. High viscosity antibacterials for cannulae
US20050042240A1 (en) * 2002-01-28 2005-02-24 Utterberg David S. High viscosity antibacterials
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
US6824763B2 (en) 2002-05-30 2004-11-30 Kimberly-Clark Worldwide, Inc. Anti-fungal powder having enhanced excipient properties
US7977532B2 (en) 2002-09-05 2011-07-12 The Procter & Gamble Company Tampon with clean appearance post use
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
BRPI0414500A (pt) * 2003-09-19 2006-11-07 Drugtech Corp formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais
US20060024372A1 (en) * 2004-07-29 2006-02-02 Utterberg David S High viscosity antibacterials
US9028852B2 (en) 2004-09-07 2015-05-12 3M Innovative Properties Company Cationic antiseptic compositions and methods of use
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
CA2590136A1 (en) 2004-12-10 2006-06-15 Talima Therapeutics, Inc. Compositions and methods for treating conditions of the nail unit
AU2006244260A1 (en) * 2005-05-09 2006-11-16 Drugtech Corporation Modified-release pharmaceutical compositions
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) * 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
EA200870153A1 (ru) * 2006-01-05 2008-12-30 Драгтек Корпорейшн Композиция и способ ее использования
CA2635994A1 (en) * 2006-01-05 2007-07-12 Drugtech Corporation Drug delivery system for bioadhesion to a vulvovaginal surface
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
SI3354276T1 (sl) 2007-11-13 2020-09-30 Meritage Pharma, Inc. Sestavki za zdravljenje gastrointestinalnega vnetja
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
CN104491864A (zh) 2008-04-21 2015-04-08 奥德纳米有限公司 用于治疗耳部疾病和病况的耳用调配物及方法
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
EP2306975A4 (en) 2008-07-21 2012-10-31 Otonomy Inc CONTROLLED RELEASE COMPOSITIONS MODULATING THE OTIC STRUCTURE AND MODULATING THE NATURAL IMMUNE SYSTEM AND METHODS OF TREATING OTIC DISORDERS
WO2010021636A1 (en) 2008-08-20 2010-02-25 The Regents Of The University Of California Corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US9498612B2 (en) 2013-03-14 2016-11-22 Hallux, Inc. Method of treating infections, diseases or disorders of nail unit
CA2993645A1 (en) 2015-07-28 2017-02-02 Otonomy, Inc. Trkb or trkc agonist compositions and methods for the treatment of otic conditions
AU2017290256A1 (en) 2016-06-29 2019-01-17 Otonomy, Inc. Triglyceride otic formulations and uses thereof
WO2019154895A1 (en) 2018-02-08 2019-08-15 Strekin Ag Gel formulation for preventing or treating hearing loss

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
ES2058503T5 (es) * 1988-03-29 1999-04-16 Univ Florida Formulaciones farmaceuticas para uso parenteral.
US5055303A (en) * 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
IT1250421B (it) * 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
ATE138561T1 (de) * 1992-02-12 1996-06-15 Janssen Cilag S P A Liposomale itraconazol formulierungen
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
FR2719999B1 (fr) * 1994-05-17 1996-08-02 Georges Serge Grimberg Composition pharmaceutique à base de gomme de guar et d'un antiacide neutralisant, à laquelle peut être ajoutée une série de principes actifs thérapeutiques.

Also Published As

Publication number Publication date
DE69506857D1 (de) 1999-02-04
FI964589A0 (fi) 1996-11-15
AP731A (en) 1999-02-08
TW438601B (en) 2001-06-07
JPH10500121A (ja) 1998-01-06
AP9600873A0 (en) 1996-10-31
HU218082B (hu) 2000-05-28
SK282623B6 (sk) 2002-10-08
US5814330A (en) 1998-09-29
ZA954023B (en) 1996-11-18
HU9603188D0 (en) 1997-01-28
KR100369703B1 (ko) 2003-04-16
ATE174790T1 (de) 1999-01-15
CN1148335A (zh) 1997-04-23
CZ336996A3 (en) 1997-02-12
CZ285606B6 (cs) 1999-09-15
HUT76326A (en) 1997-08-28
NZ285761A (en) 1997-05-26
KR970702719A (ko) 1997-06-10
AU680767B2 (en) 1997-08-07
NO964853L (no) 1996-11-15
MY113846A (en) 2002-06-29
NO309507B1 (no) 2001-02-12
NO964853D0 (no) 1996-11-15
IL113742A0 (en) 1995-08-31
JP3862748B2 (ja) 2006-12-27
PL317257A1 (en) 1997-04-01
SK146996A3 (en) 1997-05-07
EP0759741A1 (en) 1997-03-05
PL179619B1 (pl) 2000-10-31
AU2526495A (en) 1995-12-05
DK0759741T3 (da) 1999-08-23
HK1010688A1 (en) 1999-06-25
EE03304B1 (et) 2000-12-15
BG62754B1 (bg) 2000-07-31
CN1091590C (zh) 2002-10-02
WO1995031178A1 (en) 1995-11-23
DE69506857T2 (de) 1999-08-05
EP0759741B1 (en) 1998-12-23
IL113742A (en) 1999-09-22
BR9507873A (pt) 1997-09-23
FI964589A (fi) 1996-11-15
ES2127529T3 (es) 1999-04-16
OA10321A (en) 1997-10-07
BG100955A (en) 1998-04-30
RU2164418C2 (ru) 2001-03-27

Similar Documents

Publication Publication Date Title
RO117145B1 (ro) Emulsie sau soluţie apoasă, mucoadezivă
NZ234143A (en) Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
NO20033677L (no) 2-arylaminopyrimidiner for behandling av GSK3-relaterte sykdommer
UA27229C2 (uk) Фракція гіалуронової кислоти або її солі для застосування в офтальмології, спосіб одержання фракції натрієвої солі гіалуронової кислоти та фармацевтичний препарат для використання в офтальмології
IL111402A (en) Suspension of loteprednol etabonate for ear eye or nose treatment
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
MX9702349A (es) Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma.
CA2266523A1 (en) Aqueous disinfecting agent containing performic acid and peracetic acid
AU5242000A (en) Nematicidal trifluorobutenes
ATE279173T1 (de) Verfahren zur verminderung von körpergeruch
HRP20020198B1 (en) Moxifloxacin formulation containing common salt
AU7961900A (en) Skin texture-improving agents
PT1067934E (pt) Solucao anti-depressiva liquida oral
EP0136569A3 (en) Isoflavone derivatives, their production and use
TW354762B (en) Agent for prophylaxis or treatment of cataract
MXPA03008837A (es) Una composicion farmaceutica estable de pravastatina.
EP1411956B8 (en) Use of oversulfated polysaccharides as inhibitors of hiv
RO115414B1 (ro) Compoziţie farmaceutică, intranazală
DE69620573D1 (de) Mittel zur verminderung des augeninnendrucks
SE9302203D0 (sv) Composition for ophthalmic use
EP1232740A3 (en) Hair-growing agent
KR970705387A (ko) 자궁내막암의 억제 방법(methods of inhibiting endometrial cancer)
MXPA02003731A (es) Derivados novedosos de acido fusidico.
MX9605659A (es) Emulsiones mucoadhesivas que contienen ciclodextrina.
RU93058537A (ru) Применение атипамезола для лечения мужской сексуальной импотенции